We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Synpromics, Avalanche Announce Deal
News

Synpromics, Avalanche Announce Deal

Synpromics, Avalanche Announce Deal
News

Synpromics, Avalanche Announce Deal

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Synpromics, Avalanche Announce Deal"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Synpromics will develop synthetic promoters for use with Avalanche’s Ocular BioFactoryTM platform technology. Synpromics' technology creates highly specific promoters that control gene expression. These promoters are designed to be specific to the target cell type and aim to enable a precise level of control of gene expression.

Dr David Venables, CEO of Synpromics, commented, “This is our fourth collaboration in the field of gene therapy and further validation of the wide applicability of our platform. Avalanche Biotechnologies is developing next generation gene therapy technologies to treat eye diseases and we believe that Synpromics’ technology has the potential to support the development of these next generation therapeutics.”


Advertisement